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235 Evaluation of the risk of Denosumab-Associated
Hypocalcaemia
A. Krahenbule1, A. Morel1, L. Aubert1, B. Azzouz1, T. Trenque
1Regional Center of Pharmacovigilance and Pharmacoepidemiology,
Reims, France
Background: Denosumab is a human monoclonal antibody working
through inhibition of RANK-ligand osteoclast-mediated bone resorption.
As such, it is used to prevent complications of osteoporosis, bone
metastasis and giant cells tumors. However, a trade-off from this action is
an increased risk of occurrence of denosumab-associated hypocalcaemia
(DAH), which can lead to serious complications.
Objective: The present study aimed to evaluate the risk of hypocalcaemia
associated with the intake of denosumab.
Method: All cases of adverse drug reactions including hypocalcaemia
with denosumab reported to the French Pharmacovigilance Database from
1985 to the 31st of March 2017 were reviewed. Demographic and medical
information were analyzed. Renal failure, a known risk factor for DAH,
also was documented. The association between reported cases of
hypocalcaemia and denosumab use was assessed using Reporting Odds
Ratio (ROR) with 95% confidence interval.
Results: 543 cases of hypocalcemia were collected in the database of
which 53 with denosumab. Patients had a mean age of 70.36 years, males
and females were represented in similar proportions (27 females, 25 males
and 1 unknown). Concerning risk factors, renal failure was identified in 22
cases (41.5%) and severe renal failure (defined as a renal creatinine
clearance inferior to 30 ml/min) in 7 cases (13.2%). Hypocalcaemia was
significantly associated with the use of denosumab, ROR = 191.93
[142.04-259.33].
Conclusion: This study, performed on a large national pharmacovigilance
database, implies the existence of a very significant risk of hypocalcaemia
associated with the use of denosumab. Hypocalcaemia is a known side
effect of denosumab, however, the extreme value of ROR found in this
study implies its potential underestimation. Hypocalcaemia can lead to
serious complications and a risk-benefit ratio assessment, as well as close
monitoring of patients under denosumab, especially if they suffer from
renal failure, is strongly recommended.
236 Evaluation of the first EU-wide social media ADR
awareness week: 7–11 November 2016
M. Jadeja1
1MHRA, London, UK
Background: A Strengthening Collaboration for Operating Pharma-
covigilance in Europe (SCOPE) Joint Action project survey found only
four EU National Competent Authorities (NCAs) used social media to
promote ADR reporting [1]. A key deliverable from this SCOPE aware-
ness levels topic, led by the Medicines and Healthcare products Regula-
tory Agency (MHRA), was to develop a media toolkit to support NCAs
promote suspected ADR reporting nationally. Underreporting is a known
limitation of spontaneous ADR reporting systems and is linked to
awareness levels.
Objective/Aim: To develop and run an EU-wide social media campaign
to increase ADR reporting by 5% using SCOPE materials and measure its
effectiveness to provide insight into future campaigns [2].
Methods: SCOPE developed a media toolkit of campaign collateral for
NCAs consisting of animations and infographics [3,4]. The ADR aware-
ness week took place between 7 and 11 November 2016. To support
NCAs, a template press release; campaign guide; and a running plan were
developed and shared. NCAs were able to adapt to suit these to their own
needs. The campaign plan was developed and led by MHRA and for-
malised via the Heads of Medicines Agency Working Group for Com-
munications Professionals (HMA WGCP). Participation was encouraged
through SCOPE meetings and HMAWGCP. Social media channels used:
LinkedIn, Facebook, YouTube, Twitter and websites. Audiences included
patients, public and healthcare professionals. Participating NCAs moni-
tored campaign impact and reported their findings to MHRA, including
changes reporting compared to a baseline.
Results: 21 NCAs participated with common ADR messages. SCOPE
produced 24 different versions of tailored collateral in different languages
for NCAs and stakeholders such as the European Medicines Agency, the
European Commission and patient organisations. Between 15 NCAs there
was a 13% increase in suspected ADR reporting (1056 reports). The
campaign reached 2562,071 people; 337,781 viewed animation; 22,584
likes, clicks, retweets and shares. A multitude of stakeholders were
engaged to disseminate messages. Feedback on what worked well and
improvements were analysed. All respondents indicated it was worthwhile
running.
Conclusion: The SCOPE ADR awareness week campaign was a signifi-
cant success despite being the first of its kind. Recommendations include
consideration of more frequent social media use and further working
together between NCAs to make this an annual ADR awareness week at a
global level to encourage suspected ADR reporting for an improved and a
larger data pool for signal detection.
Further sources of information/References:
1. Jadeja M, Barrow P. Increasing Awareness of National Adverse Drug
Reaction Reporting Systems: Survey Report, 2015. Accessible:
http://bit.ly/2qbJqSh
2. SCOPE Awareness levels toolkit. Accessible: http://bit.ly/2qB93xf
3. SCOPE animation: http://bit.ly/2qefC5P
4. SCOPE infographics: http://bit.ly/2qebSBg
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S. French1, A. Davies1, M. Pirmohamed1
1University of Liverpool, Liverpool, UK
Background: Lower gastrointestinal toxicity—which presents clinically
as diarrhoea and colitis—is a prevalent adverse event occurring during
chemotherapeutic treatment. In addition to decreasing treatment efficacy
and patient quality of life, it contributes to the economic burden on the
NHS due to patient hospitalization and subsequent complications. Tyr-
osine kinase inhibitors are a broad class of chemotherapeutic agents for
which this is a major problem. For example Bcr-Abl inhibitors used for the
treatment of chronic myeloid leukaemia induce diarrhoea with a frequency
of 70 and 25% for bosutinib and imatinib, respectively [1]. However, the
mechanistic basis of this remains poorly understood.
Objective/Aim: Determine the processes involved in Bcr-Abl inhibitor-
induced diarrhoea
Methods: Caco-2 (human colorectal cancer) cells, which differentiate into
monolayers of polarised enterocytes, were utilized as an in vitro model.
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Cells were seeded into transwells which enable changes in paracellular
permeability to be determined by measuring electrical resistance and flux
of FITC-dextran, a fluorescently labelled polysaccharide, across the
monolayer. Changes in gene expression, protein levels and protein
localization were studied using RTqPCR, immunoblotting and immuno-
cytofluorescence, respectively.
Results: Sub-apoptotic concentrations of bosutinib increased paracellular
permeability of Caco-2 monolayers to ions and FITC-dextran (ANOVA,
p\ 0.0001), whilst imatinib was less effective at inducing this change
(ANOVA, p\ 0.001). Bosutinib decreased protein levels (ANOVA,
p\ 0.05), but not RNA levels, of cell junction protein E-cadherin—a
transmembrane protein already implicated in tyrosine kinase inhibitor-
induced diarrhoea [2,3]. In addition, mislocalization of E-cadherin was
observed after bosutinib treatment. These changes were not seen for
imatinib. As ER stress is involved in E-cadherin degradation induced by
another tyrosine kinase inhibitor (erlotinib) [3], the role of ER stress in
bosutinib-induced E-cadherin decrease was investigated. However, no
increase in ER stress markers were detected after bosutinib or imatinib
treatment.
Conclusion: Decreased intestinal barrier integrity, potentially mediated by
E-cadherin degradation, is likely an important factor in the aetiology of
bosutinib-induced diarrhoea. This information will provide useful for
identification and development of better treatments for this gastrointestinal
adverse event.
Further sources of information/References
1. Bru¨mmendorf T, Cortes J, de Souza C, Guilhot F, Duvillie´ L, Pavlov
D, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase
chronic myeloid leukaemia: results from the 24-month follow-up of
the BELA trial. Br J Haematol 2015;168:69–81
2. Hong S, Gu Y, Gao Z, Guo L, Guo W, Wu X, et al. EGFR inhibitor-
driven endoplasmic reticulum stress-mediated injury on intestinal
epithelial cells. Life Sci 2014;119:28–33
3. Fan L, Hu L, Yang B, Fang X, Gao Z, Li W, et al. Erlotinib promotes
endoplasmic reticulum stress-mediated injury in the intestinal epithe-
lium. Toxicol Appl Pharmacol 2014;278:45–52
238 Whole exome sequencing in individuals with statin-
induced myopathy
K.M. Bloch1, D. Carr1, M. Pirmohamed1, A. Morris1, C.
Maroteau2, N. Eriksson3, M. Wadelius3, C. Palmer2, A. Alfirevic1
1University of Liverpool, Liverpool, UK, 2Dundee University,
Dundee, UK, 3Uppsala University, Uppsala, Sweden
Background: Statins are widely used lipid-lowering drugs that are
effective in reducing cardiovascular disease risk. Although they are safe
and effective in the majority of patients, they can cause muscle toxicity.
The clinical spectrum of statin-induced myotoxicity varies from asymp-
tomatic elevations of creatine kinase (CK), to muscle pain or weakness
with raised CK levels and rhabdomyolysis. The precise mechanisms
underlying statin myotoxicity are unknown, but several hypotheses have
been suggested including alterations in myocyte membrane cholesterol,
depletion of isoprenoids, depletion of ubiquinone or coenzyme Q10 and
genetics such as a strong association between simvastatin-associated
myopathy and the common polymorphisms in SLCO1B1, a solute carrier
organic anion transporter has been identified [1].
Objective: The objective of the study is to try to identify genetic risk
factors that are responsible for statin-induced myopathy.
Methods: We standardized nomenclature (SRM1-SRM6) and phenotypic
definitions of statin-induced muscle toxicity [2] and recruited 779 Cau-
casian patients on statins (Table 1). Most of our patients were on sim-
vastatin (N = 511; 66%) and atorvastatin (N = 201; 26%). We performed
exome sequencing in 779 patients; 245 with statin-induced toxicity
(SRM3-SRM6) and 534 tolerant controls. DNA libraries from each sample
were pooled for exome capturing using the SureSelect v5 all-exon probe
set (Illumina). Sequencing was performed with paired-end 29125 base
reads on the Illumina HiSeq 2500 platform. The data was aligned to
indexed reference genome hg19/GRCh37 using BWA, indel realignment,
base quality score recalibration and variant calling were performed using
Genome Analysis Toolkit (GATK) v.3.5 HaplotypeCaller. The single
variant and gene-based analyses were performed using EPACTS.
Results and Conclusion: We have identified IPO9, CELF2, SIN3A and
DOCK1 as top significant genes. Future work will include validation of
the findings and a collaborative meta-analysis of whole exome sequencing
with the US cohort.
This work was funded by the EU.
Mild (SRM 3) Severe (SRM4, SRM5) Autoimmune (SRM 6) TOTAL
Case 146 91 8 245
Control NA NA NA 534
TOTAL 146 91 8 779
Further sources of information/References
1. Link E, Parish S, Armitage J, et al. SEARCH Collaborative Group
SLCO1B1 variants and statin-induced myopathy-a genomewide
study. N Engl J Med 2008;359:789–99
2. Alfirevic A, Neely D, Armitage J, Chinoy H, Cooper RG, Laaksonen
R, Carr DF, Bloch KM, Fahy J, Hanson A, Yue QY, Wadelius M,
Maitland-van Der Zee AH, Voora D, Psaty BM, Palmer CN,
Pirmohamed M. Phenotype standardization for statin-induced
myotoxicity. Clin Pharmacol Ther 2014 Oct;96:470-6.
239 A Description of New Safety Signals Detected
and Assessed by PRAC at EU level in 2014–2016
A. Mahalean1, A. Farcas1
1Drug Information Research Center, University of Medicine
and Pharmacy, Cluj-Napoca, Romania
Background: Safety monitoring of all drugs throughout their entire life-
cycle, in order to assure that the benefit-risk balance remains positive, is
mandatory in order to protect the public health. New potential risks or
changes in known risks arising from different sources are evaluated
through the signal management process. At EU level the Pharmacovigi-
lance Risk Assessment Committee (PRAC) is mandated to assess signals
and make recommendations for action following the signal assessment.
Objective: To describe all new signals detected and assessed at EU level
in 2014–2016.
Methods: Publicly available data on signals assessment and prioritization
from PRAC meeting minutes for the period January 2014-December 2016
were collected, analyzed and classified according to predefined criteria (e.g.
drug evaluated, type of signal, signal source, PRAC final recommendation).
Results: 190 new signals for 157 drugs/drugs associations/therapeutic
classes, were evaluated by PRAC in this study’s timeframe. 122 new signals
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